Systemic inflammation as fuel for acute liver injury in COVID-19
- PMID: 32873520
- PMCID: PMC7416681
- DOI: 10.1016/j.dld.2020.08.004
Systemic inflammation as fuel for acute liver injury in COVID-19
Abstract
Background: A cytokine storm conceivably contributes to manifestations of corona virus disease (COVID-19). Inflammatory cytokines such as interleukin-6 (IL-6) cause acute liver injury while serum detectability indicates systemic inflammation.
Aims: We explored a link between systemic IL-6, related acute phase proteins and liver injury in hospitalized COVID-19 patients.
Methods: 655 patients with suspected COVID-19 were screened in the emergency department at the University Hospital of Innsbruck, Austria, between February and April 2020. 96 patients (∼15%) were hospitalized with COVID-19. 15 patients required intensive-care treatment (ICT). Plasma aminotransferases, alkaline phosphatase, bilirubin, and gamma glutamyl transferase, as well as IL-6, C-reactive protein (CRP), ferritin and lactate dehydrogenase (LDH) were determined by standard clinical assays.
Results: Of all hospitalized COVID-19 patients, 41 (42%) showed elevated aspartate aminotransferase (AST) concentration. COVID-19 patients with elevated AST exhibited significantly higher IL-6 (p < 0.001), ferritin (p < 0.001), LDH (p < 0.001) and CRP (p < 0.05) serum concentrations compared to patients with normal AST. Liver injury correlated with systemic IL-6 (p < 0.001), CRP (p < 0.001), ferritin (p < 0.001) and LDH (p < 0.001) concentration. In COVID-19 patients requiring ICT, correlations were more pronounced.
Conclusion: Systemic inflammation could be a fuel for hepatic injury in COVID-19.
Keywords: Acute phase protein; COVID-19; Cytokines; Interleukin-6; Liver damage; SARS-CoV2.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
Similar articles
-
Liver Biochemistries in Hospitalized Patients With COVID-19.Hepatology. 2021 Mar;73(3):890-900. doi: 10.1002/hep.31326. Epub 2020 Nov 4. Hepatology. 2021. PMID: 32415860
-
Evaluation of hepatic enzymes activities in COVID-19 patients.Int Immunopharmacol. 2021 Aug;97:107701. doi: 10.1016/j.intimp.2021.107701. Epub 2021 Apr 21. Int Immunopharmacol. 2021. PMID: 33930704 Free PMC article.
-
Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.JAMA Netw Open. 2020 Jun 1;3(6):e2010895. doi: 10.1001/jamanetworkopen.2020.10895. JAMA Netw Open. 2020. PMID: 32492165 Free PMC article.
-
Immunological Biomarkers of COVID-19.Crit Rev Immunol. 2020;40(6):497-512. doi: 10.1615/CritRevImmunol.2020035652. Crit Rev Immunol. 2020. PMID: 33900694 Review.
-
Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.Arch Med Res. 2020 Oct;51(7):608-612. doi: 10.1016/j.arcmed.2020.06.012. Epub 2020 Jun 19. Arch Med Res. 2020. PMID: 32682575 Free PMC article. Review.
Cited by
-
Correlation between interleukin-6 expression in post-mortem core liver biopsy and degree of liver injury in patients with fatal COVID-19.Narra J. 2023 Dec;3(3):e463. doi: 10.52225/narra.v3i3.463. Epub 2023 Dec 6. Narra J. 2023. PMID: 38455630 Free PMC article.
-
Interorgan communication with the liver: novel mechanisms and therapeutic targets.Front Immunol. 2023 Dec 12;14:1314123. doi: 10.3389/fimmu.2023.1314123. eCollection 2023. Front Immunol. 2023. PMID: 38155961 Free PMC article. Review.
-
The mortality of hospitalized patients with COVID-19 and non-cirrhotic chronic liver disease: a retrospective multi-center study.PeerJ. 2023 Dec 4;11:e16582. doi: 10.7717/peerj.16582. eCollection 2023. PeerJ. 2023. PMID: 38077441 Free PMC article.
-
SARS-CoV-2 viral liver aggregates and scarce parenchymal infection implicate systemic disease as a driver of abnormal liver function.Hepatol Commun. 2023 Oct 27;7(11):e0290. doi: 10.1097/HC9.0000000000000290. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37889528 Free PMC article.
-
Demonstration of the impact of COVID-19 on metabolic associated fatty liver disease by bioinformatics and system biology approach.Medicine (Baltimore). 2023 Sep 1;102(35):e34570. doi: 10.1097/MD.0000000000034570. Medicine (Baltimore). 2023. PMID: 37657050 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
